ALNY Stock - Alnylam Pharmaceuticals, Inc.
Unlock GoAI Insights for ALNY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.25B | $1.83B | $1.04B | $844.29M | $492.85M |
| Gross Profit | $1.92B | $1.52B | $868.60M | $704.14M | $414.80M |
| Gross Margin | 85.6% | 83.0% | 83.7% | 83.4% | 84.2% |
| Operating Income | $-176,885,000 | $-282,175,000 | $-785,072,000 | $-708,652,000 | $-828,438,000 |
| Net Income | $-278,157,000 | $-440,242,000 | $-1,131,156,000 | $-852,824,000 | $-858,281,000 |
| Net Margin | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% |
| EPS | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
ALNYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $1.43 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.56 | $2.90 | +416.9% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.54 | $0.32 | +158.9% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.89 | $-0.01 | +98.9% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.62 | $0.06 | +109.7% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.92 | $-0.50 | +45.5% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-1.07 | $0.56 | +152.3% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-1.12 | $-0.16 | +85.7% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $-1.20 | $-1.10 | +8.3% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.34 | $1.15 | +185.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-1.72 | $-2.21 | -28.5% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.97 | $-1.40 | +28.9% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-2.13 | $-1.68 | +21.1% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $-1.86 | $-3.32 | -78.5% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $-1.62 | $-2.29 | -41.4% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $-1.93 | $-2.00 | -3.6% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-1.47 | $-2.16 | -46.9% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-1.51 | $-1.72 | -13.9% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-1.57 | $-1.61 | -2.5% | ✗ MISS |
Latest News
Frequently Asked Questions about ALNY
What is ALNY's current stock price?
What is the analyst price target for ALNY?
What sector is Alnylam Pharmaceuticals, Inc. in?
What is ALNY's market cap?
Does ALNY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALNY for comparison